Aardvark Therapeutics (AARD) Operating Expenses (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Operating Expenses data on file, last reported at $22.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 114.56% year-over-year to $22.5 million; the trailing twelve-month figure through Mar 2026 stood at $74.7 million (up 140.38% YoY), and the FY2025 full-year result was $62.7 million, up 175.29% from the prior year.
• Operating Expenses improved to $22.5 million in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $22.5 million in Q1 2026 to a low of $2.2 million in Q1 2024.
• A 3-year average of $12.0 million and a median of $10.5 million in 2025 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 382.27% in 2025, while the deepest fall reached 97.93% in 2025.
• Tracing AARD's Operating Expenses over 3 years: stood at $9.4 million in 2024, then surged by 97.93% to $18.7 million in 2025, then advanced by 20.1% to $22.5 million in 2026.
• Business Quant data shows AARD's Operating Expenses at $22.5 million in Q1 2026, $18.7 million in Q4 2025, and $17.7 million in Q3 2025.